Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | CARCIK trial updates: using SB-engineered CAR-T cells in patients with B-ALL

In this video, Chiara Magnani, PhD, University of Milano-Bicocca, Milan, Italy & Fondazione MBBM, Monza, Italy, reports on the results from a multi-center, Phase I/II dose-escalation trial (NCT03389035). This study analyzed the use of the sleeping beauty (SB) transposon to engineer donor-derived CD-19 CAR-T cells in pediatric and adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who relapsed after allogenic hematopoietic stem cell transplantation (HSCT). Dr Magnani first explains the reasoning behind the use of this vector and cell type, followed by a detailed description of the methodology. Dr Magnani then discusses the results from the trial, including the high tolerability of the product, as well as the safety, efficacy, complete response (CR), duration of response (DOR), and overall survival (OS) in patients. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.